drugset / Trial / NCT01439152
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
BAY94-9343 was an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells.
Timeline
- Start
- 2011-09-07
- Primary completion
- 2016-12-31
- Completion
- 2019-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anetumab Ravtansine | Monoclonal antibody | 0.15 mg/kg | Intravenous |
| Subject | Anetumab Ravtansine | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | Anetumab Ravtansine | Monoclonal antibody | 2.2 mg/kg | Intravenous |
| Subject | Anetumab Ravtansine | Monoclonal antibody | 5.5 mg/kg | Intravenous |
Indications
No indication recorded.